Literature DB >> 2023995

Increased radiation resistance in transformed and nontransformed cells with elevated ras proto-oncogene expression.

D Samid1, A C Miller, D Rimoldi, J Gafner, E P Clark.   

Abstract

The cellular Ha-ras oncogene, activated by missense mutations, has been implicated in intrinsic resistance to ionizing radiation. This study shows that the overexpression of the unmutated gene (proto-oncogene) may also be involved in how the cells respond to radiation. The experimental system consisted of mouse NIH 3T3-derived cell lines which carry multiple copies of a transcriptionally activated human c-Ha-ras proto-oncogene. Both tumorigenic (RS485) and revertant nontumorigenic subclones (PR4 and 4C3) which have high levels of ras expression exhibited a marked increase in radioresistance as measured by D0 compared to control NIH 3T3 cells. Other nontransformed cells with elevated levels of ras (phenotypically revertant line 4C8-A10) also had a significantly increased resistance to radiation, further indicating an association between ras and radioresistance. The increased radioresistance of the RS485 and phenotypic revertants could not be explained by a differential expression of the myc or metallothionein I genes or by variations in cell cycle. The correlation between increased ras proto-oncogene expression and radioresistance suggests that the ras encoded p21, a plasma membrane protein, may participate in the cellular responses to ionizing radiation.

Entities:  

Mesh:

Year:  1991        PMID: 2023995

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  9 in total

1.  Gene expression profiles in the liver of mice irradiated with (60)Co gamma rays and treated with soybean isoflavone.

Authors:  Li-Hua Song; Hong-Li Yan; Dong-Lian Cai
Journal:  Eur J Nutr       Date:  2006-09-12       Impact factor: 5.614

2.  PTK7 regulates radioresistance through nuclear factor-kappa B in esophageal squamous cell carcinoma.

Authors:  Misun Park; Hyeon-Joon Yoon; Moon Chul Kang; Junhye Kwon; Hae Won Lee
Journal:  Tumour Biol       Date:  2016-08-24

3.  Posttranscriptional down-regulation of ras oncogene expression by inhibitors of cellular glutathione.

Authors:  A C Miller; J Gafner; E P Clark; D Samid
Journal:  Mol Cell Biol       Date:  1993-07       Impact factor: 4.272

4.  Involvement of Ras in survival responsiveness to nitric oxide toxicity in pheochromocytoma cells.

Authors:  Hyun Sik Jeong; Seong Won Kim; Kwang Jin Baek; Hee Sung Lee; Nyoun Soo Kwon; Young-Myeong Kim; Hye-Young Yun
Journal:  J Neurooncol       Date:  2002-11       Impact factor: 4.130

5.  Increasing the susceptibility of the rat 208F fibroblast cell line to radiation-induced apoptosis does not alter its clonogenic survival dose-response.

Authors:  D R Aldridge; M J Arends; I R Radford
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

6.  Correlated expression of glutathione S-transferase-pi and c-Jun or other oncogene products in human squamous cell carcinomas of the head and neck: relevance to relapse after radiation therapy.

Authors:  K Miura; S Suzuki; J Tanita; H Shinkawa; K Satoh; S Tsuchida
Journal:  Jpn J Cancer Res       Date:  1997-02

Review 7.  Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.

Authors:  Abhishek A Solanki; Stanley L Liauw
Journal:  Open Access J Urol       Date:  2011-06-15

8.  Andrographolide enhances the anti-metastatic effect of radiation in Ras-transformed cells via suppression of ERK-mediated MMP-2 activity.

Authors:  Chih-Chia Yu; Chien-An Chen; Shu-Ling Fu; Hon-Yi Lin; Moon-Sing Lee; Wen-Yen Chiou; Yu-Chieh Su; Shih-Kai Hung
Journal:  PLoS One       Date:  2018-10-25       Impact factor: 3.240

9.  Inhibition of ERK1/2 or AKT Activity Equally Enhances Radiation Sensitization in B16F10 Cells.

Authors:  Bhuvanesh Sukhlal Kalal; Faraz Fathima; Vinitha Ramanath Pai; Ganesh Sanjeev; Chilakapati Murali Krishna; Dinesh Upadhya
Journal:  World J Oncol       Date:  2018-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.